FDA Releases Draft Guidance on Tissue Biopsies in Clinical Trials
The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.
Related Articles
Advancing the Future of Diagnostics and Regulatory Innovations – Friends of Cancer Research
Advancing the Future of Diagnostics and Regulatory Innovations Tuesday, February 4, 2025 10AM – 2PM ET The Ritz Carlton 1150 22nd St NW, Washington, DC…
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a…
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted…
Fred Hutch receives funding to advance Indigenous cancer health equity
Fred Hutch Cancer Center’s Lonnie A. Nelson, PhD; Jason Mendoza, MD, MPH; and Myra Parker, JD, MPH, PhD, were awarded a U19 cooperative agreement from…
The CLL hunters: finally, BTK got arrested
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Service d’Hématologie, IUCT-Oncopole, Toulouse To…
Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome
Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.
Ropeginterferon Alfa-2b Succeeds in Phase 3 Essential Thrombocythemia Trial
The SURPASS-ET trial demonstrated ropeginterferon alfa-2b’s superior efficacy over anagrelide, achieving higher durable response rates and greater reduction in JAK2 allele burden among patients with…
Cardiovascular toxicities associated with novel cellular immune therapies
Abstract. Over the past decade, T-cell–directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies
Amivantamab/Lazertinib Show OS Improvement for mNSCLC Over Osimertinib
Results from the phase 3 MARIPOSA trial found that amivantamab plus lazertinib met the final pre-specified secondary end point of overall survival in NSCLC.
